E. A. Rezukhina
E. A. Rezukhina has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Tamila V. Martynyuk
E.I. Chazov National Medical Research Center of Cardiology; N.I. Pirogov Russian National Research Medical University
12 shared publications - Oleg V. Rodnenkov
E.I. Chazov National Medical Research Center Of Cardiology
7 shared publications - V. V. Gramovich
E.I. Chazov National Medical Research Center Of Cardiology
3 shared publications - Zarina S. Valieva
Chazov National Medical Research Center of Cardiology
3 shared publications - Archil M. Shariya
E.I. Chazov National Medical Research Center Of Cardiology
2 shared publications - E. S. Allakhverdiev
E.I. Chazov National Medical Research Centre of Cardiology
2 shared publications
Latest Publications
- Open Access
- 24 February 2026
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 46-53
Analysis of quality of life indicators using various questionnaires in patients with idiopathic pulmonary hypertension.
Idiopathic pulmonary hypertension (IPAH) is a rare severe disease with a poor prognosis. Assessing quality of life (QoL) using questionnaires can significantly complement clinical, laboratory and instrumental data. Aim . To assess QoL using various questionnaires in patients with a newly and previously diagnosed IPAH. Materials and methods . 73 patients with IPAH were included in the study, all patients filled out Qol questionnaires: universal (SF-36, EQ-5D-3L) and special for patients with pulmonary hypertension (CAMPHOR, PAH-SYMPACT, EmPHasis-10). Two groups were formed, comparable by age and gender: group 1-42 patients with newly diagnosed IPAH; group 2-31 patients with a previously diagnosed IPAH. Results . Significant differences in SF-36 were found in the scale of Mental Health (52 [40; 64] % in the first group and 60 [52; 80] % in the second, p=0,02) and Mental component summary (40,8 [34,3; 49,3] % and 49,1 [41,0; 55,9] %, respectively, p=0,03). According to the EQ-5D-3L results, differences were found in the Visual Analogue Scale (VAS) and EQ-5D Index: higher values were found in the second group (the median VAS score was 50 [40; 60] % in the first group and 60 [50; 70] % in the second, p=0,006, EQ-5D Index – 0,60 [0,30; 0,71] and 0,66 [0,57; 0,76], respectively, p=0,05). No significant differences were found in the results of CAMPHOR, PAH-SYMPACT, and EmPHasis-10 in two groups. Conclusions . Pathogenetic therapy promotes improvement of functional status of patients with IPAH. Low emotional status indicators in patients with a prevalent disease indicates the need to develop a system of psychological assistance for IPAH patients.
- 24 February 2026
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 46-53
Open AccessAnalysis of quality of life indicators using various questionnaires in patients with idiopathic pulmonary hypertension.
Idiopathic pulmonary hypertension (IPAH) is a rare severe disease with a poor prognosis. Assessing quality of life (QoL) using questionnaires can significantly complement clinical, laboratory and instrumental data. Aim . To assess QoL using various questionnaires in patients with a newly and previously diagnosed IPAH. Materials and methods . 73 patients with IPAH were included in the study, all patients filled out Qol questionnaires: universal (SF-36, EQ-5D-3L) and special for patients with pulmonary hypertension (CAMPHOR, PAH-SYMPACT, EmPHasis-10). Two groups were formed, comparable by age and gender: group 1-42 patients with newly diagnosed IPAH; group 2-31 patients with a previously diagnosed IPAH. Results . Significant differences in SF-36 were found in the scale of Mental Health (52 [40; 64] % in the first group and 60 [52; 80] % in the second, p=0,02) and Mental component summary (40,8 [34,3; 49,3] % and 49,1 [41,0; 55,9] %, respectively, p=0,03). According to the EQ-5D-3L results, differences were found in the Visual Analogue Scale (VAS) and EQ-5D Index: higher values were found in the second group (the median VAS score was 50 [40; 60] % in the first group and 60 [50; 70] % in the second, p=0,006, EQ-5D Index – 0,60 [0,30; 0,71] and 0,66 [0,57; 0,76], respectively, p=0,05). No significant differences were found in the results of CAMPHOR, PAH-SYMPACT, and EmPHasis-10 in two groups. Conclusions . Pathogenetic therapy promotes improvement of functional status of patients with IPAH. Low emotional status indicators in patients with a prevalent disease indicates the need to develop a system of psychological assistance for IPAH patients.
- 26 January 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (2S)
Doctor-patient communication in pulmonary arterial hypertension
Aim . To identify the characteristics of doctor-patient communication in pulmonary arterial hypertension (PAH) based on self-understanding of their condition. Material and methods . The study included 47 patients aged 46,4±11,5 years with a verified PAH (women, 89,4%). The study was based on qualitative data obtained through questionnaires. The results were interpreted using semantic and communicative-pragmatic analysis. Results . The patients tend to focus on the semantic field of the word "Health". The response analysis allows us to conclude that participants who had already had some experience in communicating with healthcare specialists prefer to hear phrases about somatic maintenance and medical control over the disease. It does not fully fit into the patients’ worldview and the symptoms are on the periphery of their perception. Finding out the treatment expectations will enable a doctor to minimize conflicts between the two sides of the therapeutic process concerning different treatment approaches and disease perception. Conclusion . The conducted research allows a doctor to choose a communicative tactic in conducting a conversation with a PAH patient. The findings also suggest that this approach may be useful for dialogue algorithmization during any medical consultation concerning other health conditions.
- 26 January 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 30 (2S)
Doctor-patient communication in pulmonary arterial hypertension
Aim . To identify the characteristics of doctor-patient communication in pulmonary arterial hypertension (PAH) based on self-understanding of their condition. Material and methods . The study included 47 patients aged 46,4±11,5 years with a verified PAH (women, 89,4%). The study was based on qualitative data obtained through questionnaires. The results were interpreted using semantic and communicative-pragmatic analysis. Results . The patients tend to focus on the semantic field of the word "Health". The response analysis allows us to conclude that participants who had already had some experience in communicating with healthcare specialists prefer to hear phrases about somatic maintenance and medical control over the disease. It does not fully fit into the patients’ worldview and the symptoms are on the periphery of their perception. Finding out the treatment expectations will enable a doctor to minimize conflicts between the two sides of the therapeutic process concerning different treatment approaches and disease perception. Conclusion . The conducted research allows a doctor to choose a communicative tactic in conducting a conversation with a PAH patient. The findings also suggest that this approach may be useful for dialogue algorithmization during any medical consultation concerning other health conditions.
- Open Access
- 25 September 2025
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 3,p. 118-123
Non-invasive monitoring of specific therapy effectiveness in pulmonary arterial hypertension patients
Aim : to assess the dynamic of cardiac remodeling by magnetic resonance imaging (MRI) in pulmonary arterial hypertension (PAH) patients as a result of combination specific therapy including selexipag intake in long-term use (up to 12-month). Materials and methods. The study was performed on 50 PAH patients being observed at department of pulmonary hypertension and heart diseases of E.I. Chazov National Medical Research Center of Cardiology. A comparative analysis of clinical, functional and hemodynamic parameters, including cardiac MRI, was performed in all participants and resulted in selexipag administration. Results . Right ventricular end-systolic volume index (RVESVI) correlated with N-terminal pro-brain natriuretic peptide (NT-proBNP) ratio (p=0,0002), RVESVI also correlated with systolic pulmonary arterial pressure (SPAP) (p=0,0019), right ventricle stroke volume index (RVSVI) correlated with NT-proBNP ratio (pConclusion . Cardiac MRI as noninvasive method for assessment of right ventricle size and function in PAH patients either at therapy administration or therapy effectiveness assess is a promising direction for approaches development of new prognostic parameters in PAH risk stratification.
- 25 September 2025
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 3,p. 118-123
Open AccessNon-invasive monitoring of specific therapy effectiveness in pulmonary arterial hypertension patients
Aim : to assess the dynamic of cardiac remodeling by magnetic resonance imaging (MRI) in pulmonary arterial hypertension (PAH) patients as a result of combination specific therapy including selexipag intake in long-term use (up to 12-month). Materials and methods. The study was performed on 50 PAH patients being observed at department of pulmonary hypertension and heart diseases of E.I. Chazov National Medical Research Center of Cardiology. A comparative analysis of clinical, functional and hemodynamic parameters, including cardiac MRI, was performed in all participants and resulted in selexipag administration. Results . Right ventricular end-systolic volume index (RVESVI) correlated with N-terminal pro-brain natriuretic peptide (NT-proBNP) ratio (p=0,0002), RVESVI also correlated with systolic pulmonary arterial pressure (SPAP) (p=0,0019), right ventricle stroke volume index (RVSVI) correlated with NT-proBNP ratio (pConclusion . Cardiac MRI as noninvasive method for assessment of right ventricle size and function in PAH patients either at therapy administration or therapy effectiveness assess is a promising direction for approaches development of new prognostic parameters in PAH risk stratification.
- Open Access
- 2 October 2024
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 3,p. 82-86
Successful heart lung transplantation in patient with pulmonary capillary hemangiomatosis: case presentation
Our observation demonstrates a case of a 40-year-old female with pulmonary arterial hypertension World Health Organization functional class III, who was admitted to NMRC of Cardiology repeatedly due to disease progression including dyspnea worsening, onset of desaturation and chest pain during exertion on riociguat (7.5 mg daily), bosentan (115 mg daily) and selexipag (400 mcg daily) therapy. Computed tomography scan revealed pulmonary capillary hemangiomatosis pattern and the diagnosis was revealed. We performed PAH-specific therapy escalation which resulted in selexipag withdrawal, bosentan dose titration to 250 mg daily with good treatment tolerability. Due to unreleased treatment goals, high-risk status and heart failure progression, the patient was referred to Shumakov National Medical Research Center of Transplantology and Artificial Organs, where successful heart lung transplant was performed in may 2022. The postoperative period elapsed without complication, the patient discharged from hospital and is staying alive in stable condition. Pulmonary capillary hemangiomatosis is a rare cause of pulmonary arterial hypertension with pure prognosis. PAH-specific treatment should be avoided due to increased risk of rapid disease progression and pulmonary oedema. The only one definitive treatment is lung or heart lung transplantation.
- 2 October 2024
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 3,p. 82-86
Open AccessSuccessful heart lung transplantation in patient with pulmonary capillary hemangiomatosis: case presentation
Our observation demonstrates a case of a 40-year-old female with pulmonary arterial hypertension World Health Organization functional class III, who was admitted to NMRC of Cardiology repeatedly due to disease progression including dyspnea worsening, onset of desaturation and chest pain during exertion on riociguat (7.5 mg daily), bosentan (115 mg daily) and selexipag (400 mcg daily) therapy. Computed tomography scan revealed pulmonary capillary hemangiomatosis pattern and the diagnosis was revealed. We performed PAH-specific therapy escalation which resulted in selexipag withdrawal, bosentan dose titration to 250 mg daily with good treatment tolerability. Due to unreleased treatment goals, high-risk status and heart failure progression, the patient was referred to Shumakov National Medical Research Center of Transplantology and Artificial Organs, where successful heart lung transplant was performed in may 2022. The postoperative period elapsed without complication, the patient discharged from hospital and is staying alive in stable condition. Pulmonary capillary hemangiomatosis is a rare cause of pulmonary arterial hypertension with pure prognosis. PAH-specific treatment should be avoided due to increased risk of rapid disease progression and pulmonary oedema. The only one definitive treatment is lung or heart lung transplantation.
- Open Access
- 22 November 2023
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 4,p. 56-63
Assessment of the effectiveness of PAH-specific therapy, including selexipag, in patients with idiopathic pulmonary hypertension according to a comprehensive examination using Raman spectroscopy
Aim: to assess the effectiveness of PAH-specific therapy, including selexipag, based on data from a comprehensive examination and assessment of oxygen transport function in patients with IPAH using Raman spectroscopy.Materials and methods. The study was performed on fourteen (n=14) patients diagnosed with IPAH who were on combination PAH-specific therapy, including selexipag. The diagnosis was established in accordance with the algorithm proposed in the Russian guidelines for the diagnosis and treatment of PAH (2020). A comparative analysis of clinical and hemodynamic parameters, including an assessment of hemoglobin conformation using Raman spectroscopy, was performed in all participants.Results. The use of Selexipag as part of a combined PAH-specific therapy caused significant changes in the conformation of Hb including a decrease in the probability of a “dome-shaped” heme conformation due to changes in the group vibrations of heme pyrrole groups (I1375/I1172) and stretching vibrations of vinyl groups (I1580/I1550), as well as an increase globin density.Conclusion. The use of the prostacyclin receptor agonist selexipag as part of a combination PAH-specific therapy for patients with IPH was associated with improvement in clinical, functional and molecular parameters (taking into account the assessment of oxygen transport function and hemoglobin conformation by Raman spectroscopy).
- 22 November 2023
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 4,p. 56-63
Open AccessAssessment of the effectiveness of PAH-specific therapy, including selexipag, in patients with idiopathic pulmonary hypertension according to a comprehensive examination using Raman spectroscopy
Aim: to assess the effectiveness of PAH-specific therapy, including selexipag, based on data from a comprehensive examination and assessment of oxygen transport function in patients with IPAH using Raman spectroscopy.Materials and methods. The study was performed on fourteen (n=14) patients diagnosed with IPAH who were on combination PAH-specific therapy, including selexipag. The diagnosis was established in accordance with the algorithm proposed in the Russian guidelines for the diagnosis and treatment of PAH (2020). A comparative analysis of clinical and hemodynamic parameters, including an assessment of hemoglobin conformation using Raman spectroscopy, was performed in all participants.Results. The use of Selexipag as part of a combined PAH-specific therapy caused significant changes in the conformation of Hb including a decrease in the probability of a “dome-shaped” heme conformation due to changes in the group vibrations of heme pyrrole groups (I1375/I1172) and stretching vibrations of vinyl groups (I1580/I1550), as well as an increase globin density.Conclusion. The use of the prostacyclin receptor agonist selexipag as part of a combination PAH-specific therapy for patients with IPH was associated with improvement in clinical, functional and molecular parameters (taking into account the assessment of oxygen transport function and hemoglobin conformation by Raman spectroscopy).
- Open Access
- 11 October 2023
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 3,p. 44-52
Possibility of evaluation of oxygen transport function in PAH patients on effective selexipag-based therapy
In the complex pathogenesis of idiopathic pulmonary arterial hypertension (IPAH), which includes changes in biochemical and biophysical processes in various cell types as the cause of structural and functional impairment, inflammation and thrombosis of the pulmonary vessels, hypoxia also plays an important role due to conformational changes in hemoglobin molecules with changes in their structure and oxygen transport function impairment.Aim: Using the method of Raman (Raman scattering) spectroscopy, to study changes in the conformation and ability of hemoglobin (Hb) to bind oxygen in blood erythrocytes from the cubital vein in IPAH patients and healthy people. Materials and methods: The study included 39 patients with newly diagnosed IPAH with functional class I – 2 patients, II – 13 patients, III – 22 patients, IV – 2 patients. 15 patients were treatment naive. In 24 patients a “washout” period of trial therapy was conducted for 5–7 days. The control group included 10 healthy volunteers.Results: It was established that the Raman spectra of Hb of whole blood erythrocytes and isolated red blood cells (RBC) of IPAH patients have significant differences from the control group. The IPAH group was characterized by an increase in the probability of finding heme in a «dome-shaped form», which is typical for the deoxygenated form of Hb, changes in the conformation of globin and the porphyrin macrocycle were revealed. A significant role in the change in the oxygen-transport function of Hb in IPAH was played by a change in the conformation of membrane-bound hemoglobin, which was characterized by an increase in the contribution of symmetrical vibrations of pyrrole rings in hemoporphyrin relative to the control, which required further study. Probably, the reason for the decrease in the ability of the oxygen transport function of membrane-bound hemoglobin was the decrease in the efficiency of electrostatic interaction with the protein of band 3. In clinical case positive changes in spectroscopy parameters were shown in IPAH patient with the effective use of selexipag.Conclusions: For the first time, the possibility of using a non-invasive method of Raman spectroscopy to study changes in the oxygen transport function of erythrocytes in IPAH patients has been proven, which can serve as an additional method in the diagnostic algorithm of this disease.
- 11 October 2023
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 3,p. 44-52
Open AccessPossibility of evaluation of oxygen transport function in PAH patients on effective selexipag-based therapy
In the complex pathogenesis of idiopathic pulmonary arterial hypertension (IPAH), which includes changes in biochemical and biophysical processes in various cell types as the cause of structural and functional impairment, inflammation and thrombosis of the pulmonary vessels, hypoxia also plays an important role due to conformational changes in hemoglobin molecules with changes in their structure and oxygen transport function impairment.Aim: Using the method of Raman (Raman scattering) spectroscopy, to study changes in the conformation and ability of hemoglobin (Hb) to bind oxygen in blood erythrocytes from the cubital vein in IPAH patients and healthy people. Materials and methods: The study included 39 patients with newly diagnosed IPAH with functional class I – 2 patients, II – 13 patients, III – 22 patients, IV – 2 patients. 15 patients were treatment naive. In 24 patients a “washout” period of trial therapy was conducted for 5–7 days. The control group included 10 healthy volunteers.Results: It was established that the Raman spectra of Hb of whole blood erythrocytes and isolated red blood cells (RBC) of IPAH patients have significant differences from the control group. The IPAH group was characterized by an increase in the probability of finding heme in a «dome-shaped form», which is typical for the deoxygenated form of Hb, changes in the conformation of globin and the porphyrin macrocycle were revealed. A significant role in the change in the oxygen-transport function of Hb in IPAH was played by a change in the conformation of membrane-bound hemoglobin, which was characterized by an increase in the contribution of symmetrical vibrations of pyrrole rings in hemoporphyrin relative to the control, which required further study. Probably, the reason for the decrease in the ability of the oxygen transport function of membrane-bound hemoglobin was the decrease in the efficiency of electrostatic interaction with the protein of band 3. In clinical case positive changes in spectroscopy parameters were shown in IPAH patient with the effective use of selexipag.Conclusions: For the first time, the possibility of using a non-invasive method of Raman spectroscopy to study changes in the oxygen transport function of erythrocytes in IPAH patients has been proven, which can serve as an additional method in the diagnostic algorithm of this disease.
- Open Access
- 26 May 2023
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 2,p. 48-55
The clinical profile of pulmonary arterial hypertension in newly diagnosed patients with connective tissue disease from the point of view of the cardiologist
Aim: to evaluate demographic and disease characteristics in pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD) patients.Materials and methods: the study enrolls 68 patients with PAH-CTD. These patients were diagnosed in department of pulmonary hypertension and heart disease of the E.I. Chazov National Medical Research Centre of cardiology. Clinical, functional and hemodynamic characteristics of PAH patients were examined. The diagnosis was confirmed according to Eurasian (2019) and Russian (2020) guidelines for the diagnosis and treatment of pulmonary hypertension.Results: Of 68 patients with CTD 35 (51,5%) had systemic sclerosis, 11 (16,2%) - mixed CTD, 22 (32,3%) - other CTD. The median time from PAH onset to first visit to health care worker was 4 months, the median time from first visit to PAH diagnosis was 7,5 months. The median age was 59,5 years, 94,1% patients were women. The median 6-minute walking distance (6MWD) was 345 (259,25-400,00) m, which was corresponding to WHO functional class III, the median Borg dyspnea index was 5 (3,0-6,0). 12 (17,7%) patients did not undergo 6MWD due to severity of their condition. According to right heart catheterization data the median mean pulmonary arterial pressure was 51,0 (35,5-62,0) mmHg, the median cardiac index was 2,1 (1,7-2,5) liter/min/m2, the median pulmonary vascular resistance was 11,48 (5,99-15,71) Wood units. According to several risk stratification calculators, the vast majority of patients were at high risk of 1-year mortality: due to risk status, PAH-specific therapy was initiated to 88,3% patients: 42,7% received double and 8,8% - triple PAH-specific therapy.Conclusions: In Russian clinical practice, PAH-CTD is characterized by late- onset diagnosis. Newly diagnosed patients have significant functional and hemodynamic impairment, high risk of 1-year mortality, which results in combined PAH-specific therapy initiation.
- 26 May 2023
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 2,p. 48-55
Open AccessThe clinical profile of pulmonary arterial hypertension in newly diagnosed patients with connective tissue disease from the point of view of the cardiologist
Aim: to evaluate demographic and disease characteristics in pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD) patients.Materials and methods: the study enrolls 68 patients with PAH-CTD. These patients were diagnosed in department of pulmonary hypertension and heart disease of the E.I. Chazov National Medical Research Centre of cardiology. Clinical, functional and hemodynamic characteristics of PAH patients were examined. The diagnosis was confirmed according to Eurasian (2019) and Russian (2020) guidelines for the diagnosis and treatment of pulmonary hypertension.Results: Of 68 patients with CTD 35 (51,5%) had systemic sclerosis, 11 (16,2%) - mixed CTD, 22 (32,3%) - other CTD. The median time from PAH onset to first visit to health care worker was 4 months, the median time from first visit to PAH diagnosis was 7,5 months. The median age was 59,5 years, 94,1% patients were women. The median 6-minute walking distance (6MWD) was 345 (259,25-400,00) m, which was corresponding to WHO functional class III, the median Borg dyspnea index was 5 (3,0-6,0). 12 (17,7%) patients did not undergo 6MWD due to severity of their condition. According to right heart catheterization data the median mean pulmonary arterial pressure was 51,0 (35,5-62,0) mmHg, the median cardiac index was 2,1 (1,7-2,5) liter/min/m2, the median pulmonary vascular resistance was 11,48 (5,99-15,71) Wood units. According to several risk stratification calculators, the vast majority of patients were at high risk of 1-year mortality: due to risk status, PAH-specific therapy was initiated to 88,3% patients: 42,7% received double and 8,8% - triple PAH-specific therapy.Conclusions: In Russian clinical practice, PAH-CTD is characterized by late- onset diagnosis. Newly diagnosed patients have significant functional and hemodynamic impairment, high risk of 1-year mortality, which results in combined PAH-specific therapy initiation.
- Open Access
- 2 March 2023
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 94-99
Patient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation
Aim: to evaluate demographic and disease characteristics in pulmonary arterial hypertension (PAH) patients, for which selexipag is prescribed as PAH-specific treatment.Materials and methods: the study enrolls 73 patients with PAH, where there were 49 patients with idiopathic PAH and 24 patients with associated conditions. These patients were diagnosed in department of pulmonary hypertension and heart disease of the National Medical Research Centre of cardiology named after academician E.I. Chazov of Ministry of Health. Clinical, functional and hemodynamic characteristics of PAH patients were examined. The diagnosis was confirmed according to Eurasian (2019) and Russian (2020) guidelines for the diagnosis and treatment of pulmonary hypertension.Results: At selexipag initiation, median of patient`s age was 43 years, 86,3% were female. Etiological analysis revealed idiopathic PAH in 49 (67,1%) patients, 24 (32,9%) had associated conditions: 14 (19,2%) had connective tissue disease‒associated PAH, 6 (8,2%) had PAH after correction of the initial heart defect, 4 (5,5%) had HIV-associated PAH. The median 6-minute walking distance (6MWD) was 370 (300,0-443,75) m, which was corresponding to WHO functional class III, the median Borg dyspnea index was 5 (3,0-6,0). 7 (9,6%) patients did not undergo 6MWD due to severity of their condition. According to right heart catheterization data the median mean pulmonary arterial pressure was 58,5 (48,25-65,0) mmHg, the median right atrium pressure was 7,5 (5,0-10,0) mmHg, the median venous oxygen saturation 58,5% (56,0-66,0), the median cardiac index was 2,0 (1,6-2,5) liter/min/ m2, the median pulmonary vascular resistance was 15,0 (10,3-19,1) Wood units. At selexipag initiation, according to Eurasian (2019) and Russian (2020) guidelines 1 (1,3%) was at low risk, 21 (28,8%) were at intermediate risk and 51 (69,9%) were at high risk of 1-year mortality. Due to risk status, selexipag was initiated in double (50,7%) and triple (49,3%) PAH-specific therapy.Conclusions: At selexipag initiation, PAH-patients typically have WHO FC III and are at high risk, despite receiving PAH-specific treatment. Selexipag was prescribed as part of a combination regimen in most patients.
- 2 March 2023
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 94-99
Open AccessPatient and disease characteristics of pulmonary arterial hypertension patients for prostacyclin receptor agonist selexipag treatment initiation
Aim: to evaluate demographic and disease characteristics in pulmonary arterial hypertension (PAH) patients, for which selexipag is prescribed as PAH-specific treatment.Materials and methods: the study enrolls 73 patients with PAH, where there were 49 patients with idiopathic PAH and 24 patients with associated conditions. These patients were diagnosed in department of pulmonary hypertension and heart disease of the National Medical Research Centre of cardiology named after academician E.I. Chazov of Ministry of Health. Clinical, functional and hemodynamic characteristics of PAH patients were examined. The diagnosis was confirmed according to Eurasian (2019) and Russian (2020) guidelines for the diagnosis and treatment of pulmonary hypertension.Results: At selexipag initiation, median of patient`s age was 43 years, 86,3% were female. Etiological analysis revealed idiopathic PAH in 49 (67,1%) patients, 24 (32,9%) had associated conditions: 14 (19,2%) had connective tissue disease‒associated PAH, 6 (8,2%) had PAH after correction of the initial heart defect, 4 (5,5%) had HIV-associated PAH. The median 6-minute walking distance (6MWD) was 370 (300,0-443,75) m, which was corresponding to WHO functional class III, the median Borg dyspnea index was 5 (3,0-6,0). 7 (9,6%) patients did not undergo 6MWD due to severity of their condition. According to right heart catheterization data the median mean pulmonary arterial pressure was 58,5 (48,25-65,0) mmHg, the median right atrium pressure was 7,5 (5,0-10,0) mmHg, the median venous oxygen saturation 58,5% (56,0-66,0), the median cardiac index was 2,0 (1,6-2,5) liter/min/ m2, the median pulmonary vascular resistance was 15,0 (10,3-19,1) Wood units. At selexipag initiation, according to Eurasian (2019) and Russian (2020) guidelines 1 (1,3%) was at low risk, 21 (28,8%) were at intermediate risk and 51 (69,9%) were at high risk of 1-year mortality. Due to risk status, selexipag was initiated in double (50,7%) and triple (49,3%) PAH-specific therapy.Conclusions: At selexipag initiation, PAH-patients typically have WHO FC III and are at high risk, despite receiving PAH-specific treatment. Selexipag was prescribed as part of a combination regimen in most patients.
- Open Access
- 7 March 2022
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 80-89
Pulmonary arterial hypertension: challenges and achievements 2021
Symposium dedicated to pulmonary arterial hypertension took place at the 9th Russian Congress on Pulmonary hypertension on December 14, 2021. In this review key points from Chazova I.E., Martynyuk T.V., Valieva Z.S., Gramovich V.V.`s reports are presented, in which information about PAH treatment goals achievement, COVID-19 pandemic challenges impact on routine clinical practice is demonstrated. In this review current situation in pulmonary arterial hypertension treatment goals and regular risk stratification importance are observed, based on the latest clinical trials combined specific therapy including selective prostacyclin receptor agonist selexipag is demonstrated. special attention is paid to pulmonary hypertension patients’ treatment during COVID-19 pandemic, regular risk stratification necessity is mentioned including remote patient monitoring in order to perform timely escalation in PAH-specific treatment in order to achieve low-risk status and to improve the prognosis of PAH patients.
- 7 March 2022
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 1,p. 80-89
Open AccessPulmonary arterial hypertension: challenges and achievements 2021
Symposium dedicated to pulmonary arterial hypertension took place at the 9th Russian Congress on Pulmonary hypertension on December 14, 2021. In this review key points from Chazova I.E., Martynyuk T.V., Valieva Z.S., Gramovich V.V.`s reports are presented, in which information about PAH treatment goals achievement, COVID-19 pandemic challenges impact on routine clinical practice is demonstrated. In this review current situation in pulmonary arterial hypertension treatment goals and regular risk stratification importance are observed, based on the latest clinical trials combined specific therapy including selective prostacyclin receptor agonist selexipag is demonstrated. special attention is paid to pulmonary hypertension patients’ treatment during COVID-19 pandemic, regular risk stratification necessity is mentioned including remote patient monitoring in order to perform timely escalation in PAH-specific treatment in order to achieve low-risk status and to improve the prognosis of PAH patients.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 17 (4)
Therapeutic potential of nitric oxide pathway management in pulmonary arterial hypertension: from nitric oxide to its synthetic analog — Oxacom
Современные подходы к лечению пациентов с легочной артериальной гипертензией (ЛАГ) — редким заболеванием с неблагоприятным прогнозом, — включают применение специфических вазодилататоров, механизм действия которых направлен на один из путей патогенеза этого заболевания. Эндогенный оксид азота (NO) — одна из важнейших молекул с широкой палитрой воздействия на тонус сосудов, тромбоцитарную и лейкоцитарную активность, пролиферацию гладкомышечных клеток и фибробластов, а также воспалительный и иммунный ответ. Недостаток NO, находящийся в основе хронического спазма сосудов, пролиферации, тромбоза in situ при ЛАГ, является мишенью для создания новых препаратов. Перспективным направлением при ЛАГ считается применение прямых аналогов эндогенных доноров NO живых организмов. Таким препаратом становится синтетический динитрозильный комплекс железа с глутатионом — Оксаком Применение внутривенных инфузий Оксакома в течение 5 последовательных дней может рассматриваться в качестве лекарственной стратегии для пациентов с клиническим ухудшением ЛАГ с целью снижения давления в легочной артерии, стабилизации гемодинамики, что приведет к сокращению сроков пребывания в стационаре.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- Vol. 17 (4)
Therapeutic potential of nitric oxide pathway management in pulmonary arterial hypertension: from nitric oxide to its synthetic analog — Oxacom
Современные подходы к лечению пациентов с легочной артериальной гипертензией (ЛАГ) — редким заболеванием с неблагоприятным прогнозом, — включают применение специфических вазодилататоров, механизм действия которых направлен на один из путей патогенеза этого заболевания. Эндогенный оксид азота (NO) — одна из важнейших молекул с широкой палитрой воздействия на тонус сосудов, тромбоцитарную и лейкоцитарную активность, пролиферацию гладкомышечных клеток и фибробластов, а также воспалительный и иммунный ответ. Недостаток NO, находящийся в основе хронического спазма сосудов, пролиферации, тромбоза in situ при ЛАГ, является мишенью для создания новых препаратов. Перспективным направлением при ЛАГ считается применение прямых аналогов эндогенных доноров NO живых организмов. Таким препаратом становится синтетический динитрозильный комплекс железа с глутатионом — Оксаком Применение внутривенных инфузий Оксакома в течение 5 последовательных дней может рассматриваться в качестве лекарственной стратегии для пациентов с клиническим ухудшением ЛАГ с целью снижения давления в легочной артерии, стабилизации гемодинамики, что приведет к сокращению сроков пребывания в стационаре.